Drug Trial Radar · NCT02951052
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
618
Actual
Start
Oct 28, 2016
Primary completion
May 29, 2018
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Janssen Pharmaceuticals; GlaxoSmithKline
- First posted
- Nov 1, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult subjects with current viral suppression on a regimen with 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent, remain suppressed upon switching to a two-drug intramuscular (IM) long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). This is a Phase 3, multi-phase, randomized, open label, active-controlled, multicenter, parallel-group, non-inferiority study in HIV-1, antiretroviral therapy (ART)-adult subjects who are stably suppressed on a current antiretroviral (ARV) regimen. This study is designed to demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks (Q4W: monthly) compared with maintenance of current ARV regimen containing 2 NRTIs plus an INI, NNRTI, or a PI. Eligible subjects will be randomized (1:1) into the Maintenance Phase at Day 1 to either continue current ART or switch to initiate oral therapy with CAB 30 mg + RPV 25 mg once daily for 4 Weeks followed by Q4 weekly (monthly) CAB LA + RPV LA injections. Following the Maintenance phase at Week 52, subjects who were randomized to continue their current ART regimen will be given an option to switch to CAB LA + RPV LA injections. Those subjects would transition to LA dosing, beginning with 4 weeks oral CAB + RPV therapy at Week 52, and receive the first IM CAB LA + RPV LA injections at Week 56.
Conditions
- Infection, Human Immunodeficiency Virus
- HIV Infections
Interventions
Cabotegravir (CAB) tabletDrug
It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat
Rilpivirine (RPV) tabletDrug
It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with "TMC" and the other side with "25". Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose
Cabotegravir - Injectable Suspension (CAB LA)Drug
It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection
Rilpivirine - Injectable Suspension (RPV LA)Drug
It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
2 NRTIs plus an INI, NNRTI, or PIDrug
Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus: * INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen) * NNRTI (either the initial or second cART regimen) * Boosted PI (or atazanavir \[ATV\] unboosted) (either the initial or second PI-based cART regimen)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48Time frame: Week 48
Locations
113 sites in 13 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Palm Springs, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Fort Lauderdale, Florida
GSK Investigational Site
Ft. Pierce, Florida
GSK Investigational Site
Sarasota, Florida
GSK Investigational Site
Vero Beach, Florida
GSK Investigational Site
Macon, Georgia
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Buffalo, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
Chapel Hill, North Carolina
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Allentown, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Annandale, Virginia
GSK Investigational Site
Lynchburg, Virginia
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Ciudad Autonoma Buenos Aires, Argentina
GSK Investigational Site
Rosario, Argentina
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.